Skip to content
DataLookout
Menu

NCT03315026

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 14 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2026 to Oct 2027
    • Eligibility criteria expanded, about 27 words
  2. Notable Primary and study completion dates: Oct 2025 to Oct 2026v16
  3. Notable Primary and study completion dates: Oct 2024 to Oct 2025v15
  4. Notable Primary and study completion dates: Oct 2023 to Oct 2024v14
  5. Notable Primary and study completion dates: Oct 2021 to Oct 2023v11
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Primary and study completion dates: Oct 2020 to Oct 2021v10
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  3. Minor Enrollment target: 28 to 30v7
  4. Notable Primary and study completion dates: Oct 2019 to Oct 2020v6
  5. Notable Primary and study completion dates: Oct 2018 to Oct 2019v5
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Eligibility criteria expanded, about 41 words
    • Start date changed from estimate of Dec 2017 to Dec 14, 2017
    • Site details revised
    v4
  7. Minor Start date: Nov 2017 to Dec 2017v3
  8. Minor Start date: Oct 2017 to Nov 2017v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

number of patients with improved symptoms
Timeframe: 30 days post ASCT

Arms and interventions

SiltuximabExperimental

Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).

Drugs: Siltuximab

Behavioral: The M.D. Anderson Symptom Inventory (MDASI)

Sites

1 site in 1 country

  • Memorial Sloan Kettering Cancer CenterNew York, New York, United States